New Multi-Mission Beechcraft King Air Demonstrator Unveiled at Paris Air Show
Over the last few years, we have seen solid European demand of our Cargo Door King Air 360C for essential air ambulance services.
Share
'The King Air's acquisition and operation cost, combined with excellent speed, range and payload capacity make it an excellent value for a wide range of special missions,' said Bob Gibbs, vice president, Special Missions Sales. 'The best-selling turboprop serves as an ideal platform for intelligence, surveillance and reconnaissance, utility transport, training and more. Over the last few years, we have seen solid European demand of our Cargo Door King Air 360C for essential air ambulance services.'
Endless Special Missions Possibilities on Display
When government, military and commercial customers want airborne solutions for critical missions, they turn to Textron Aviation. The Beechcraft King Air on display is fitted with extended range (ER) fuel tanks, a factory-installed extended utility nose capable of housing a variety of sensors up to a 20-inch EO/IR sensor and a lift kit to retract, factory-installed wing hardpoint provisions and a cargo door that supports air ambulance and freight operations to enhance mission flexibility.
Powered by PT6A-67A engines with dual oil coolers, the aircraft offers hot/high airfield performance as well as impressive climb performance and cruising speeds.
Interior features include a mission rack with displays and a mission computer, Original Equipment Manufacturer (OEM) VIP seating, AvFab and LifePort mission seats and a LifePort medevac stretcher. The cockpit is compatible with Night Vision Imaging Systems (NVIS).
King Air Leadership
More than 7,800 Beechcraft King Air turboprops have been delivered to customers since 1964, making it the best-selling business turboprop family in the world. The fleet has surpassed 66 million flight hours in its 60 years, serving roles in all branches of the U.S. military and flying both commercial and special missions.
Textron Aviation returns to the Paris Air Show as the industry leader with more than 1,700 Cessna and Beechcraft turbine aircraft in Europe and more than 255,000 aircraft delivered worldwide. In France, nearly 200 Cessna and Beechcraft turbine aircraft support a wide variety of missions for commercial, government and military customers.
About Textron Aviation
We inspire the journey of flight. For more than 95 years, Textron Aviation has empowered our collective talent across the Beechcraft, Cessna and Hawker brands to design and deliver the best aviation experience for our customers. With a range that includes everything from business jets, turboprops, and high-performance pistons, to special missions, military trainer and defense products, Textron Aviation has the most versatile and comprehensive aviation product portfolio in the world and a workforce that has produced more than half of all general aviation aircraft worldwide. Customers in more than 170 countries rely on our legendary performance, reliability and versatility, along with our trusted global customer service network, for affordable, productive and flexible flight.
For more information, visit www.txtav.com | specialmissions.txtav.com | defense.txtav.com | scorpion.txtav.com.
About Textron Inc.
Textron Inc. is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO, and Textron Systems.
For more information, visit: www.textron.com.
Certain statements in this press release may project revenues or describe strategies, goals, outlook or other non-historical matters; these forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update them. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to our ability to keep pace with our competitors in the introduction of new products and upgrades with features and technologies desired by our customers; volatility in the global economy or changes in worldwide political or macroeconomic conditions that adversely impact demand for our products; and risks related to our international business, including establishing and maintaining facilities in locations around the world and relying on joint venture partners, subcontractors, suppliers, representatives, consultants and other business partners in connection with international business, including in emerging market countries.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 minutes ago
- Business Wire
Proofpoint and Optiv Surpass $1 Billion in Historical Sales
SUNNYVALE, Calif.--(BUSINESS WIRE)-- Proofpoint, Inc., a leading cybersecurity and compliance company, today announced that Optiv, the cyber advisory and solutions leader, has surpassed $1 billion in cumulative sales of Proofpoint's industry-leading cybersecurity platform. This milestone underscores the depth, strength, and strategic alignment of the Proofpoint-Optiv partnership in securing organizations against human-centric threats. Proofpoint's human-centric security platform, combined with Optiv's outcome-driven services and deep expertise, have helped thousands of organizations modernize their security posture, consolidate vendor spend, and reduce complexity. For more than a decade, Proofpoint and Optiv have partnered to deliver Proofpoint's best-in-class solutions that address the most critical risks organizations face: protecting their people and defending their data. In an era where 90% of breaches involve human error or behavior, and threats continue to grow and become more sophisticated due to AI, that mission has never been more critical. Proofpoint's human-centric security platform has become a key part of the modern cybersecurity architecture along with XDR and SASE. Together, Proofpoint and Optiv empower organizations across the U.S., Canada, and Latin America with advanced technologies and services that secure users, defend data, and reduce risk. 'The strength of our relationship with Optiv is rooted in mutual trust, shared innovation, and a relentless focus on customer success,' said Blake Sallé, chief revenue officer at Proofpoint. 'Surpassing the $1 billion mark is a testament to Optiv's understanding of the risk landscape and their ability to deliver Proofpoint's market-leading solutions at scale. We congratulate the entire Optiv team on this tremendous achievement and look forward to continuing our joint mission of protecting people and defending data.' Proofpoint's human-centric security platform, combined with Optiv's outcome-driven services and deep expertise, have helped thousands of organizations modernize their security posture, consolidate vendor spend, and reduce complexity. Through this collaboration, customers gain access to fully managed security solutions tailored to the specific risks facing their people and data—across email, cloud, identity, apps, and beyond. 'Reaching the $1 billion milestone with Proofpoint is more than a sales achievement – it's a reflection of a trusted partnership built on shared values, innovation, and a relentless focus on client success,' said John Hurley, chief revenue officer at Optiv. 'Together, we've helped organizations strengthen their cybersecurity posture in a rapidly evolving threat landscape, and we're just getting started.' As organizations embrace new technologies to drive efficiency and innovation, cybersecurity must evolve in tandem. The enduring partnership between Optiv and Proofpoint ensures customers have access to integrated, AI-powered, unified solutions that provide the critical visibility and insights needed to effectively solve today's sophisticated threats and risks targeting people. Proofpoint's focus on continuous innovation has been validated by industry accolades—six Leader positions in analyst reports and 11 industry awards so far this year, including: To find out more about Proofpoint's human-centric cybersecurity platform through Optiv, please visit: About Proofpoint, Inc. Proofpoint, Inc. is a leading cybersecurity and compliance company that protects organizations' greatest assets and biggest risks: their people. With an integrated suite of cloud-based solutions, Proofpoint helps companies around the world stop targeted threats, safeguard their data, and make their users more resilient against cyber attacks. Leading organizations of all sizes, including 85 percent of the Fortune 100, rely on Proofpoint for people-centric security and compliance solutions that mitigate their most critical risks across email, the cloud, social media, and the web. More information is available at Proofpoint is a registered trademark or tradename of Proofpoint, Inc. in the U.S. and/or other countries. All other trademarks contained herein are the property of their respective owners.
Business Wire
6 minutes ago
- Business Wire
Important Notice of Dividend Announcement to shareholder of Xtrackers (IE) plc
LONDON--(BUSINESS WIRE)-- Registered in Dublin, Ireland as an open-ended variable capital umbrella investment company with limited liability and as an umbrella fund with segregated liability between sub-funds. Registration Number 393802. Registered Office as above. Directors: Tom Murray (Irish), Michael Whelan (Irish), Gerry Grimes (Irish), Philippe Ah-Sun (British), Julien Boulliat (French) and Roberto Cesca (Italian). Xtrackers (IE) plc Investment Company with Variable Capital Registered Office: 78 Sir John Rogerson's Quay, Dublin 2, Ireland Registration number: 393802 (the ' Company ') Important Notice to Shareholders of the Company Dividend Announcement 5 August 2025 Dividend announcement with regard to the following Funds of the Company The Board of Directors wishes to inform Shareholders that a dividend per share for certain Classes of Shares and Funds will be paid, as set out below. Please note the following dates which apply to all of the below: Ex-dividend date: 20 August 2025 Record date: 21 August 2025 Payment date: 4 September 2025 Fund Xtrackers MSCI World Screened UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.1116 ISIN Code IE00BCHWNQ94 Expand Fund Xtrackers MSCI USA Energy UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.6232 ISIN Code IE00BCHWNS19 Expand Fund Xtrackers MSCI USA Financials UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.2258 ISIN Code IE00BCHWNT26 Expand Fund Xtrackers MSCI USA Health Care UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.3933 ISIN Code IE00BCHWNW54 Expand Fund Xtrackers MSCI USA Minimum Volatility UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.3714 ISIN Code IE00BDB7J586 Expand Fund Xtrackers USD High Yield Corporate Bond UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.1958 ISIN Code IE00BDR5HM97 Expand Fund Xtrackers MSCI USA Banks UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.3137 ISIN Code IE00BDVPTJ63 Expand Fund Xtrackers ESG USD Emerging Markets Bond Quality Weighted UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.2418 ISIN Code IE00BD4DX952 Expand Fund Xtrackers USD Corporate Bond Short Duration SRI PAB UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.3386 ISIN Code IE00BF8J5974 Expand Fund Xtrackers MSCI USA Consumer Staples UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.4785 ISIN Code IE00BGQYRQ28 Expand Fund Xtrackers MSCI USA Consumer Discretionary UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.2194 ISIN Code IE00BGQYRR35 Expand Fund Xtrackers MSCI USA Information Technology UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.2305 ISIN Code IE00BGQYRS42 Expand Fund Xtrackers S&P Europe ex UK UCITS ETF Share Class 1D Denomination Currency EUR Amount/Share (gross) 1.2498 ISIN Code IE00BGV5VM45 Expand Fund Xtrackers MSCI World UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.4923 ISIN Code IE00BK1PV551 Expand Fund Xtrackers MSCI Japan Screened UCITS ETF Share Class 1D Denomination Currency JPY Amount/Share (gross) 25.5250 ISIN Code IE00BPVLQD13 Expand Fund Xtrackers MSCI Japan Screened UCITS ETF Share Class 2D - GBP Hedged Denomination Currency GBP Amount/Share (gross) 0.2477 ISIN Code IE00BPVLQF37 Expand Fund Xtrackers USD Corporate Bond UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.1484 ISIN Code IE00BZ036H21 Expand Fund Xtrackers MSCI World UCITS ETF Share Class 2D - GBP Hedged Denomination Currency GBP Amount/Share (gross) 0.1071 ISIN Code IE00BZ1BS790 Expand Fund Xtrackers MSCI Nordic UCITS ETF Share Class 1D Denomination Currency EUR Amount/Share (gross) 1.1481 ISIN Code IE00B9MRHC27 Expand Fund Xtrackers MSCI USA Industrials UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.4638 ISIN Code IE00BCHWNV48 Expand Fund Xtrackers MSCI USA Communication Services UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.3070 ISIN Code IE00BNC1G707 Expand Fund Xtrackers MSCI Emerging Markets UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.0726 ISIN Code IE000GWA2J58 Expand Fund Xtrackers S&P 500 Equal Weight UCITS ETF Share Class 1D - GBP Hedged Denomination Currency GBP Amount/Share (gross) 0.0252 ISIN Code IE000N5GJDD7 Expand Fund Xtrackers USD Corporate Green Bond UCITS ETF Share Class 1D - GBP Hedged Denomination Currency GBP Amount/Share (gross) 0.1696 ISIN Code IE000X63FXN4 Expand Fund Xtrackers MSCI USA ESG UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.0222 ISIN Code IE000UMV0L21 Expand Fund Xtrackers USD High Yield Corporate Bond UCITS ETF Share Class 4D - GBP Hedged Denomination Currency GBP Amount/Share (gross) 0.1081 ISIN Code IE00BG04LV15 Expand Fund Xtrackers MSCI USA Climate Transition UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.1112 ISIN Code IE000GYDNJS5 Expand Fund Xtrackers MSCI Japan Climate Transition UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.0402 ISIN Code IE0006FDYJF8 Expand Fund Xtrackers S&P 500 Equal Weight UCITS ETF Share Class 2D Denomination Currency USD Amount/Share (gross) 0.2938 ISIN Code IE000CXLGK86 Expand Fund Xtrackers USD Corporate Bond UCITS ETF Share Class 5D - GBP Hedged Denomination Currency GBP Amount/Share (gross) 0.0848 ISIN Code IE00BG04LY46 Expand Fund Xtrackers MSCI USA High Dividend Yield ESG UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.1429 ISIN Code IE000V04SL39 Expand Fund Xtrackers MSCI World High Dividend Yield ESG UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.3040 ISIN Code IE000NS5HRY9 Expand Fund Xtrackers MSCI World ex USA UCITS ETF Share Class 1D Denomination Currency USD Amount/Share (gross) 0.1083 ISIN Code IE000Z0FC0G5 Expand Should you have any queries in this regard please do not hesitate to contact your relationship manager directly. Capitalised terms used in this letter shall have the meaning ascribed to them in the current Prospectus of the Company unless the context otherwise requires. We thank you for your continuing support of the Company. Yours faithfully, _______________ Director For and on behalf of Xtrackers (IE) plc Contact Information Xtrackers (IE) plc 78 Sir John Rogerson's Quay Dublin 2, Ireland
Business Wire
37 minutes ago
- Business Wire
Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016
AMSTERDAM, ZUG, Switzerland & GDAŃSK, Poland--(BUSINESS WIRE)--Polpharma Biologics S.A. ('Polpharma Biologics') announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed biosimilar to vedolizumab, an integrin receptor antagonist, (reference product: Entyvio®*), a biologic therapy indicated for moderate to severe ulcerative colitis and Crohn's disease. Under the terms of the agreement, Polpharma Biologics will lead development and manufacturing of PB016, while Fresenius Kabi will hold exclusive commercialization rights worldwide, excluding Middle East & North Africa. 'This partnership reinforces our mission to broaden access to high-quality biologics that improve patient outcomes globally,' said Konstantin Matentzoglu, Supervisory Board Member of Polpharma Biologics Group. 'Fresenius Kabi's deep commercialization experience and commitment to biosimilars make them an ideal partner for bringing PB016 to patients worldwide. Together, we are taking an important step toward addressing the rising burden of chronic inflammatory diseases.' The agreement builds on Polpharma Biologics' growing biosimilar portfolio and proven development capabilities. The company has previously brought forward multiple biosimilars — including ranibizumab and natalizumab — across global markets in partnership with leading pharmaceutical companies. This strategic collaboration strengthens both companies' commitments to expanding global access to affordable biologic medicines while supporting healthcare system sustainability. *Entyvio® is a registered trademark of Takeda. About Polpharma Biologics: Polpharma Biologics is an international biotechnology company with integrated operations in the European Union (EU), developing and manufacturing biosimilar medicines. Using patented solutions and state-of-the-art platform technologies, Polpharma Biologics develops biosimilar products to treat a range of conditions in major therapeutic areas. Programs at Polpharma Biologics start in cell line development and transition through technical and clinical development to commercial-scale production preparing drugs for future commercial partnerships with global pharmaceutical organizations. The expertise of Polpharma Biologics lies in the development and manufacture of medicines based on microbial and mammalian expression systems. With its cell line development center in the Netherlands and two centers of development and manufacturing in Poland, Polpharma Biologics creates growth and development opportunities for biotechnology specialists. Learn more at About Fresenius Kabi: As part of the global healthcare company Fresenius, Fresenius Kabi specializes in (bio)pharmaceuticals, medical technologies and nutrition products for critical and chronic conditions. The company's products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. For more information, please visit Important Note This press release is for informational purposes only and does not constitute promotional material for PB016 in Poland or any other jurisdiction. The commercialization of proposed vedolizumab biosimilar PB016 is solely the responsibility of Fresenius Kabi, the marketing authorization holder, in accordance with all applicable laws and regulations. Disclaimer This press release is issued from Polpharma Biologics Group and is intended to provide worldwide information to healthcare professionals, media and (potential) investors about our global business in relation to drug development and manufacturing expertise. Although Polpharma Biologics Group is not a public company as of this date, recipients should understand that this press release contains certain forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). These statements involve inherent risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the approval and commercialization of the medicinal product, market reception, competition, changes in economic conditions and applicable laws, global regulatory developments, contractual risks and dependencies from third parties. Polpharma Biologics undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release. Moreover, Polpharma Biologics wishes to emphasize that this press release is for informational purposes only and shall not be construed as making any representation, warranties, or guarantees, either express or implied, regarding the potential approval, market reception, commercialization, or success of the medicinal product or any other product or therapy.
